9:41
progenra.com
Screenshot of progenra.com
progenra.com favicon

progenra.com

16 technologies
VerifiedVisit1.0K/mo$2M1216 Tech8 Leads
Deep Dive

Progenra: The Tiny Biotech Targeting Parkinson's

A 12-person team taking on the ubiquitin proteasome system with $1.9M in revenue

In a biotech landscape dominated by billion-dollar IPOs and sprawling pharmaceutical giants, Progenra operates with surgical precision. This 12-person team has quietly carved out a niche in the ubiquitin proteasome system—a complex cellular mechanism that could unlock new treatments for Parkinson's disease.

12
employees
$1.9M
annual revenue
73%
direct traffic
1,018
monthly visits

"They're not playing the venture capital lottery—they're building revenue while cracking one of neurodegeneration's hardest problems."

The Ubiquitin Play

Progenra isn't chasing the latest CRISPR headlines or mRNA hype. Their focus is the ubiquitin proteasome system—the cell's quality control machinery that tags and destroys damaged proteins. When this system fails, misfolded proteins accumulate, leading to Parkinson's and other neurodegenerative diseases. Their strategy: develop Parkin activators that boost this system's natural cleanup function. It's elegant, targeted, and scientifically rigorous.

Funding Without Frenzy

The Michael J. Fox Foundation backing their Parkin activator research validates their approach. But here's what's interesting: with $1.9M in revenue and no disclosed VC funding, they're likely generating income through partnerships or early-stage collaborations. This isn't a company burning cash on animal models and PR—they're monetizing their medicinal chemistry expertise while advancing their pipeline. For investors, this signals discipline. For founders, it's a masterclass in capital efficiency.

  • President & CEO Tauseef Butt leads a lean, chemistry-heavy team
  • Published in ACS 2019 Medicinal Chemistry Reviews—academic credibility matters
  • Heavy Twitter/X presence suggests active scientific engagement
  • 73% direct traffic indicates a small, highly engaged audience
No flashy AI drug discovery platform
Deep expertise in medicinal chemistry
No massive preclinical war chest
Validated by top neurodegeneration foundation
No consumer-facing brand or app
Revenue-positive while advancing science

The traffic data reveals everything about their stage: 1,018 monthly visits with 73% direct traffic means this isn't a company playing SEO games. Their audience is precise—researchers, potential partners, and the neurodegeneration community. The top search term is a typo of their own domain name, which either speaks to brand recall or a fascinating SEO problem they haven't solved yet. Either way, they're not optimizing for scale—they're optimizing for science.

The Anti-Biotech Biotech

12 people, $1.9M revenue, one mission: crack the ubiquitin code for Parkinson's. No hype, just chemistry.

What tech stack does Progenra use?

19 detected
Programming Languages1
Analytics & Marketing1
UI Libraries2
JavaScript Libraries3
Tracking & Analytics3
G
Google Analytics
G
Google Tag Manager
G
Google Analytics

How much traffic does Progenra get?

Traffic & Engagement

1.0K
Monthly Visits
1.1
Pages/Visit
0:00
Avg. Duration
39%
Bounce Rate
Monthly Traffic Trend-12%
1.2K
Oct 2025
Oct
1.4K
Nov 2025
Nov
1.0K
Dec 2025
Dec

Traffic Sources

Search
12%
Direct
73%
Social
9%
Referrals
5%
Email
0%
Paid
1%

Where is Progenra's audience located?

🌍100.0%

What keywords does Progenra rank for?

5 keywords
1proqyntra.com1.2K vol
2tauseef butt130 vol
3progenra20 vol
4the mitochondrion in aging and disease340 vol
5goldberg repurpose savnanah260 vol

How is Progenra's SEO?

Open Graph Image

OG Image preview
og:image

https://progenra.com/wp-content/uploads/2025/05/approval_hires.png

Meta Tags

title15 chars

Home | Progenra

description158 chars

Home | Progenra - Dedicated to Finding New Medicines Through Targeting the Ubiquitin Proteasome System to fill unmet needs in a spectrum of therapeutic areas.

languageEN-US

H1 Tags

h1The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease
h1Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
h1Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.

Schema Types

Unknown

Who works at Progenra?

Loading leads...

What do customers think of Progenra?

No Trustpilot reviews available for this company.

Frequently Asked Questions about Progenra

What is Progenra's Revenue?
Progenra generates approximately $2M in annual revenue. With 12 employees, that's $155,000 per employee.
What does Progenra do?
Home | Progenra - Dedicated to Finding New Medicines Through Targeting the Ubiquitin Proteasome System to fill unmet needs in a spectrum of therapeutic areas.
How fast is Progenra growing?
Progenra employee count has changed by -8% year over year.
What technologies does Progenra use?
Progenra uses 16 technologies across their website including Fonts, Programming Languages, CMS. Key technologies include Font Awesome, PHP, WordPress.
Who are Progenra's competitors?
Progenra's main competitors include Western Oncolytics Ltd., Holganix, LifeLens Technologies, Montrose Broadcasting Corp, World Fusion. These companies operate in similar markets and compete for the same customer base.

Export Data

Unlock all exports

Download CSVs, JSONs & full reports

How to contact Progenra?

What are Progenra's key pages?

Export progenra.com Data

Download the complete tech stack, analytics, leads, and company data for progenra.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.

Raw JSON Data

Click "Show" to view the raw API response data

About progenra.com

Home | Progenra - Dedicated to Finding New Medicines Through Targeting the Ubiquitin Proteasome System to fill unmet needs in a spectrum of therapeutic areas.

Company Overview

progenra.com
Website
#14,273,914
Global Rank
1.0K
Monthly Visitors
16
Technologies
8+
Employees

progenra.com Key Pages

Contact progenra.com

Technology Stack

progenra.com uses 16 technologies across their website including Font Awesome, PHP, WordPress, and more.

Fonts

Font Awesome

Programming Languages

PHP

CMS

WordPress

Analytics & Marketing

Google Analytics

Performance

Lazy Loading, Priority Hints

Web Standards

Twitter Cards, RSS, PWA

Traffic & Audience

1.0K
Monthly Visits
39%
Bounce Rate
1.1
Pages/Visit
0:00
Avg. Duration

progenra.com receives approximately 1.0K monthly visitors and ranks #14,273,914 globally. The website has a bounce rate of 39% with visitors viewing an average of 1.1 pages per visit. Users spend an average of 0:00 on the site.

The majority of progenra.com's traffic comes from .

Frequently Asked Questions

What is progenra.com?
Home | Progenra - Dedicated to Finding New Medicines Through Targeting the Ubiquitin Proteasome System to fill unmet needs in a spectrum of therapeutic areas.
What technologies does progenra.com use?
progenra.com uses 16 technologies including Font Awesome, PHP, and 10 more. View the full tech stack analysis above.
How do I contact progenra.com?
You can contact progenra.com via email at [email protected] or through their contact page.
What are progenra.com's social media accounts?
progenra.com is active on twitter, facebook, linkedin. You can find links to all their social media profiles in the social section above.
How popular is progenra.com?
progenra.com receives approximately 1.0K monthly visitors and ranks #14,273,914 globally. Traffic is declining by 26.9% month-over-month.

Related Searches

progenra.com pricingprogenra.com reviewsprogenra.com alternativesprogenra.com loginprogenra.com careerswhat is progenra.comprogenra.com tech stackprogenra.com contactprogenra.com vs competitorsprogenra.com featureshow to use progenra.comprogenra.com integrations

This page provides publicly available information about progenra.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit progenra.com directly at https://progenra.com.